Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 15/20 | 0.72 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.60 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.60 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.72 |
| ▸ | SRC | P12931 | 5/20 | 0.72 |
| ▸ | TEK | Q02763 | 5/20 | 0.72 |
| ▸ | KDR | P35968 | 3/20 | 0.72 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.62 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.62 |
| ▸ | FGR | P09769 | 1/20 | 0.60 |
| ▸ | CSK | P41240 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5801750 | 1.00 | BTK (0.72) | BTKLCKSRCTEKKDR | |
| Maleic Acid SCHEMBL5801744 | 1.00 | BTK (0.72) | BTKLCKSRCTEKKDR | |
| Maleic Acid SCHEMBL5801746 | 1.00 | BTK (0.72) | BTKLCKSRCTEKKDR | |
| SCHEMBL6430150 | 0.94 | BTK (0.82) | BTKLCKSRCTEKKDR | |
| SCHEMBL5804554 | 0.94 | BTK (0.82) | BTKLCKSRCTEKKDR | |
| SCHEMBL5804551 | 0.94 | BTK (0.82) | BTKLCKSRCTEKKDR | |
| SCHEMBL25468776 | 0.87 | BTK (0.81) | BTKLCKSRCTEKKDR | |
| Fumaric Acid SCHEMBL6431673 | 0.86 | LCK (0.75) | BTKLCKSRCTEKKDR | |
| Maleic Acid SCHEMBL6431672 | 0.86 | LCK (0.75) | BTKLCKSRCTEKKDR | |
| SCHEMBL6433141 | 0.84 | BTK (1.00) | BTKLCKSRCTEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885FLT3 67/4885JAK3 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.